Kak..massive potential ?... so you see what Big Pharmas see ?
A good starting point is Novartis valuing Gamida Cell (currently conducting two Phase I/II trials) at $233m (15% for $35m).
How would you value 12 applications in P2 ( 3currently in Phase III) ?
...there will come a point where it so compelling that it will be clear to all that MSB is undervalued.
DYOR.
Kak..massive potential ?... so you see what Big Pharmas see ? A...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |